PURPOSE: The aim of this study is to report on a collective of 20 children from Belarus who had developed papillary thyroid carcinoma with pulmonary metastases after the Chernobyl disaster. In all children fractionated radioiodine therapy (RIT) was ceased before achieving complete remission due to a lack of further effects of (131)I therapy and an increased risk of pulmonary fibrosis. METHODS: The 20 children (12 girls) were treated with (131)I using 50 MBq/kg body weight for thyroid remnant ablation and 100 MBq/kg for further therapy in intervals of 5-12 months. After five to six courses and a cumulative activity of about 24 GBq (131)I no further RIT was conducted; the median thyroglobulin (TG) was 56 μg/l at this time. All patients were followed for at least 10 years after cessation of RIT using diagnostic whole-body scintigraphy, CT of the chest, lung function testing and stimulated TG measurements every 1-3 years. RESULTS: During follow-up after the last RIT a continuous decline of values for TG levels of ∼35% per year was observed between individual visits. The median Tg level at the time of cessation of (131)I therapy was 56 µg/l; however, at the last visit 16 of 20 patients had a TG level ≤10 μg/l (median 2.4 μg/l). Neither on diagnostic radioiodine whole-body scan nor on CT was progression of lung metastases observed. No significant pulmonary fibrosis developed. CONCLUSION: In spite of incomplete remission of thyroid cancer at cessation of RIT, a continuing spontaneous decline of TG and clinically stable partial remissions were observed in this collective of children. Therefore, if RIT does not show further effects, the administration of further courses should be handled restrictively.
PURPOSE: The aim of this study is to report on a collective of 20 children from Belarus who had developed papillary thyroid carcinoma with pulmonary metastases after the Chernobyl disaster. In all children fractionated radioiodine therapy (RIT) was ceased before achieving complete remission due to a lack of further effects of (131)I therapy and an increased risk of pulmonary fibrosis. METHODS: The 20 children (12 girls) were treated with (131)I using 50 MBq/kg body weight for thyroid remnant ablation and 100 MBq/kg for further therapy in intervals of 5-12 months. After five to six courses and a cumulative activity of about 24 GBq (131)I no further RIT was conducted; the median thyroglobulin (TG) was 56 μg/l at this time. All patients were followed for at least 10 years after cessation of RIT using diagnostic whole-body scintigraphy, CT of the chest, lung function testing and stimulated TG measurements every 1-3 years. RESULTS: During follow-up after the last RIT a continuous decline of values for TG levels of ∼35% per year was observed between individual visits. The median Tg level at the time of cessation of (131)I therapy was 56 µg/l; however, at the last visit 16 of 20 patients had a TG level ≤10 μg/l (median 2.4 μg/l). Neither on diagnostic radioiodine whole-body scan nor on CT was progression of lung metastases observed. No significant pulmonary fibrosis developed. CONCLUSION: In spite of incomplete remission of thyroid cancer at cessation of RIT, a continuing spontaneous decline of TG and clinically stable partial remissions were observed in this collective of children. Therefore, if RIT does not show further effects, the administration of further courses should be handled restrictively.
Authors: David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle Journal: Thyroid Date: 2009-11 Impact factor: 6.568
Authors: K D Newman; T Black; G Heller; R G Azizkhan; G W Holcomb; C Sklar; V Vlamis; G M Haase; M P La Quaglia Journal: Ann Surg Date: 1998-04 Impact factor: 12.969
Authors: E Baudin; C Do Cao; A F Cailleux; S Leboulleux; J P Travagli; M Schlumberger Journal: J Clin Endocrinol Metab Date: 2003-03 Impact factor: 5.958
Authors: Hong Song; Bin He; Andrew Prideaux; Yong Du; Eric Frey; Wayne Kasecamp; Paul W Ladenson; Richard L Wahl; George Sgouros Journal: J Nucl Med Date: 2006-12 Impact factor: 10.057
Authors: Yuri E Demidchik; Eugene P Demidchik; Christoph Reiners; Johannes Biko; Mariko Mine; Vladimir A Saenko; Shunichi Yamashita Journal: Ann Surg Date: 2006-04 Impact factor: 12.969
Authors: Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita Journal: Thyroid Date: 2015-07 Impact factor: 6.568
Authors: Scott A Rivkees; Ernest L Mazzaferri; Frederik A Verburg; Christoph Reiners; Markus Luster; Christopher K Breuer; Catherine A Dinauer; Robert Udelsman Journal: Endocr Rev Date: 2011-08-31 Impact factor: 19.871
Authors: Bryan R Haugen; Erik K Alexander; Keith C Bible; Gerard M Doherty; Susan J Mandel; Yuri E Nikiforov; Furio Pacini; Gregory W Randolph; Anna M Sawka; Martin Schlumberger; Kathryn G Schuff; Steven I Sherman; Julie Ann Sosa; David L Steward; R Michael Tuttle; Leonard Wartofsky Journal: Thyroid Date: 2016-01 Impact factor: 6.568
Authors: Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg Journal: Nat Rev Endocrinol Date: 2011-08-09 Impact factor: 43.330
Authors: Frederik A Verburg; Uwe Mäder; Markus Luster; Heribert Hänscheid; Christoph Reiners Journal: Eur J Nucl Med Mol Imaging Date: 2015-06-13 Impact factor: 9.236
Authors: Suzanne P MacFarland; Andrew J Bauer; N Scott Adzick; Lea F Surrey; Jessica Noyes; Ken Kazahaya; Sogol Mostoufi-Moab Journal: J Clin Endocrinol Metab Date: 2018-08-01 Impact factor: 5.958
Authors: M Motazedian; B Shafiei; P Vatankhah; S Hoseinzadeh; M Mirzababaee; L Fathollahi; M Ansari; N Baharfar; F Tabeie; I Neshandar Asli Journal: Med Oncol Date: 2013-02-20 Impact factor: 3.064